Modafinil for the Treatment of Alcohol Use Disorders

Alcohol Use Disorder Clinical Trial

Official title:

Modafinil for the Treatment of Alcohol Use Disorders: Targeting Impaired Response Inhibition

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03424681
• Other study ID #: FP00002746
• Status: Completed
• Phase: Phase 2
• Start date: December 11, 2017
• Est. completion date: August 31, 2018

Study information

• Verified date: May 2020
• Source: The Mind Research Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Alcohol use disorder (AUD) is a major cause of morbidity and mortality and more treatments are needed, especially pharmacotherapies. There are a variety of efficacious treatments for AUD, but effect sizes are small, and vary from study to study. Medications may be more effective if particular subgroups of AUD are targeted. Identifying the mechanisms of action of a particular medication will help identify the subtypes more likely to respond to therapy. Global impulse control is a rational treatment target, and improving it is a likely mechanisms by which some medications for AUD work, especially in subtypes of AUD with impaired impulse control at baseline. Modafinil is a medication that is FDA approved for the treatment of narcolepsy, and is relatively safe and tolerable. There is reason to believe it may improve impulse control, and underlying neural circuitry, and may work best to improve alcohol use outcomes in AUD with poor impulse control. The overall aim of this study is to investigate the effects of modafinil on task performance and the integrity of neural circuits mediating response inhibition in treatment-seeking AUD with poor response inhibition, to establish target engagement. Secondary aims are to measure whether target engagement mediates improvement in alcohol use outcomes, and to utilize machine learning to identify neural and behavioral markers which best predict treatment outcomes. Twenty-four individuals with AUD and impaired response inhibition will be enrolled in the study, randomized to modafinil or placebo, and treated for 6 weeks. Functional magnetic resonance imaging brain scans during a response inhibition task and during rest will be obtained at baseline and 2 weeks. Aversive stimuli will be included in the response inhibition task to assure that efficacy generalizes to several conditions. Diffusion imaging and arterial spin labeling sequences will also be obtained. Investigators predict that modafinil will significantly increase brain activity in the medial and lateral prefrontal cortex during response inhibition, thereby establishing target engagement, and that it will improve alcohol use outcomes. Findings will provide information about whether or not a larger R01 trial investigating the efficacy of modafinil for individuals with AUD and impaired response inhibition is warranted.

Description:

see above.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: August 31, 2018
• Est. primary completion date: August 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females age 18-65 meeting Diagnostic and Statistical Manual V criteria for moderate or severe AUD in the past year

• Interested in cutting down or quitting

• Able to provide voluntary informed consent

• Have at least 4 heavy drinking days (= 5 drinks per day for men, and 4 for women) in the past 60 days

• Stop signal reaction time on a stop signal task>233

Exclusion Criteria:

• Severe neurological conditions (severe traumatic brain injury/stroke/active seizure disorder)

• Heart disease [mitral valve prolapse, left ventricular hypertrophy, cardiac arrhythmias, angina, myocardial infarction, unstable angina, cardiac syncope or pre-syncope, any electrocardiogram (ECG) finding that suggests the presence of one of these conditions]

• Uncontrolled hypertension (systolic blood pressure >160, diastolic blood pressure >100)

• Heart rate greater than 70% of the maximum expected for age [0.70(220-age)]

• Chronic renal or hepatic failure

• Recent pancreatitis

• Insulin-dependent diabetes

• Other urgent medical problems

• Elevated liver function tests (AST or ALT greater than 4 times normal; modafinil is metabolized primarily by the liver)

• Schizophrenia, schizoaffective disorder, Bipolar I disorder, suicidal thoughts in the last month

• Current moderate or severe other substance use disorder (SUD) (except nicotine or marijuana)

• Active legal problems with the potential to result in incarceration

• Pregnancy or lactation, or child bearing age and not on birth control

• Current daily use of anti-craving medications, stimulants, benzodiazepines, opiates, anti-psychotics; current daily use of tricyclic antidepressants, bupropion, monoamine oxidase inhibitors, serotonin and norepinephrine reuptake inhibitors, or therapeutic doses (for bipolar disorder) of mood stabilizers

• Taking a medication contraindicated for use with modafinil

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism

Intervention

Drug:
• Modafinil
Modafinil 300 mg by mouth daily

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Mind Research Network	Albuquerque	New Mexico

Sponsors (1)

Lead Sponsor	Collaborator
The Mind Research Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Relapse	Time to relapse, starting 7 days after treatment initiation (after medication has reached maximum tolerated dose), to heavy drinking days (>4 standard drinks for men, >3 standard drinks for women); abstinent is coded as 9*7=63; dropout not included	over 9 weeks
Secondary	Drinks Per Drinking Day	drinks per drinking day weeks 4-6	Weeks 4-6
Secondary	Drinks Per Week	drinks per week weeks 4-6	Weeks 4-6
Secondary	Percent Days Abstinent	percent days abstinent weeks 4-6	Weeks 4-6